All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
The combination of bortezomib with melphalan and prednisolone (VMP) is a standard induction regimen for patients with newly diagnosed multiple myeloma (NDMM). Tadao Ishida and colleagues investigated whether a reduced intensity dosing of VMP could provide an improved safety profile while maintaining the efficacy, which is particularly of interest for older patients. An article published in Annals of Hematology, reported results of the phase II study of VMP induction therapy followed by lenalidomide plus dexamethasone (Rd) consolidation and lenalidomide maintenance in transplant-ineligible patients with NDMM.1
The article is in line with the current editorial theme on the Multiple Myeloma (MM) Hub, which focuses on developments to improve frontline treatment for NDMM.
Patient and disease characteristics:
Table 1. Patient and disease characteristics
Ig, immunoglobulin; ISS, international staging system *data available for 80 patients |
||
Characteristics |
Patients (N = 83) |
|
---|---|---|
Median age (range), years |
74 (61–84) |
|
Age ≥ 75, % |
37.3 |
|
Female gender, % |
55.4 |
|
Myeloma type IgG IgA Light chain only |
65.1 22.9 12.0 |
|
ISS stage, % I II III |
30.1 49.4 20.5 |
|
High-risk cytogenetics, %* t(4;14) and/or del(17p) t(4;14) and/or del(17p), and/or gain(1q) |
23.8 46.3 |
Table 2. Best response during therapy
CR, complete response; PD, progressive disease; PR, partial response; Rd, lenalidomide plus dexamethasone; sCR, stringent CR; SD, stable disease; VGPR, very good partial response; VMP, bortezomib with melphalan and prednisolone |
|||
Best response |
VMP induction (n = 83) |
Rd consolidation (n = 57) |
Lenalidomide maintenance (n = 57) |
---|---|---|---|
sCR |
2.4 |
12.3 |
29.8 |
CR |
7.2 |
8.8 |
15.8 |
VGPR |
18.0 |
24.6 |
21.1 |
PR |
39.8 |
47.4 |
28.1 |
SD |
27.7 |
5.3 |
5.2 |
PD |
0 |
1.8 |
0 |
Unevaluable |
4.8 |
0 |
0 |
Table 3. Grade 3 and 4 TEAEs
Rd, lenalidomide plus dexamethasone; VMP, bortezomib with melphalan and prednisolone |
||||||
TEAE
|
VMP induction (N = 83) |
Rd consolidation (n = 57) |
Lenalidomide maintenance (n = 54) |
|||
---|---|---|---|---|---|---|
Grade 3 |
Grade 4 |
Grade 3 |
Grade 4 |
Grade 3 |
Grade 4 |
|
Anemia |
28.9 |
0 |
3.5 |
0 |
7.4 |
0 |
Neutropenia |
12 |
3.6 |
1.8 |
0 |
18.5 |
5.6 |
Thrombocytopenia |
4.8 |
1.2 |
0 |
0 |
1.9 |
0 |
Infection |
0 |
0 |
0 |
0 |
1.9 |
0 |
Diarrhea |
0 |
0 |
0 |
0 |
1.9 |
0 |
Constipation |
1.2 |
0 |
0 |
0 |
0 |
0 |
Nausea |
1.2 |
0 |
0 |
0 |
0 |
0 |
Peripheral neuropathy |
2.4 |
0 |
0 |
0 |
0 |
0 |
Skin rash |
1.2 |
1.2 |
5.3 |
0 |
1.9 |
0 |
The results from the study revealed that reduced-intensity VMP followed by Rd consolidation and lenalidomide maintenance is an effective treatment for patients with NDMM who are not eligible for transplant. Patients who achieved ≥ VGPR prior to lenalidomide maintenance appeared to benefit most from this additional therapy. The authors suggest that this regimen would be particularly suitable for older patients due to a more manageable toxicity profile than current standard of care regimens.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?